Ahngook Pharmaceutical, CHA Biotech and Alvogen participated in the main bidding of DreamPharma acquisition
It was identified that Ahngook Pharmaceutical, CHA Biotech and Alvogen participated in the main bidding of DreamPharma acquisition which was closed on June 25.
Dream Pharma is a subsidiary of Hanwha Group, of which Hanwha holds 100% of the shares. It recorded sales of 93 billion won, business pr...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
